Venetoclax, navitoclax, and obatoclax represented significant advances in apoptosis-targeted therapy, with venetoclax emerging as the most clinically successful agent. However, resistance mechanisms and side effects were significant challenges, necessitating further preclinical and clinical studies to optimize the therapeutic potential of these agents.

2 days ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)

Venclexta (venetoclax) • navitoclax (ABT 263) • obatoclax (GX 15-070)

GLIOTARG: Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas (clinicaltrials.gov)

P=N/A, N=1000, Active, not recruiting, Blokhin's Russian Cancer Research Center

2 days ago

New trial

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

IDH wild-type

Avastin (bevacizumab) • carboplatin • irinotecan

Surgical Pembro +/- Olaparib w TMZ for rGBM (clinicaltrials.gov)

P2, N=78, Recruiting, L. Nicolas Gonzalez Castro, MD, PhD | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Aug 2026

2 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)

EGFR mutation • EGFR amplification • IDH wild-type

Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide

Effect of stRess and exeRcize on the Outcome After Chemo-Radiation (clinicaltrials.gov)

P=N/A, N=42, Completed, Maastricht Radiation Oncology | Recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

2 days ago

Trial completion • Trial completion date • Trial primary completion date

IDH wild-type

EAY131-A: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (clinicaltrials.gov)

P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027

2 days ago

Trial completion date

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR L861Q • EGFR S768I

Gilotrif (afatinib)

Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients. (PubMed, Neuro Oncol)

This study delineates a complex spatial architecture of brain tissue with post-treatment changes and its discrepancies from progressive GB, thus facilitating future research into novel treatment strategies.

2 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR expression • IDH wild-type

temozolomide

18ï ¢-Glycyrrhetinic acid suppresses glioblastoma by regulating p38 signaling pathway: an integrative approach combining network analysis, transcriptomics, and experimental assessment. (PubMed, Front Pharmacol)

Mechanistically, GA downregulated MAPK11 expression, activated p38 signaling pathway, and subsequently suppressed the MEK/ERK signaling pathway. This study demonstrats that GA exerted potent anti-GBM effects by regulating p38 signaling pathway, provides novel mechanistic insights, and positions its as a promising therapeutic candidate against GBM.

2 days ago

Journal

MAPK1 (Mitogen-activated protein kinase 1) • MAPK11 (Mitogen-Activated Protein Kinase 11)

Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma. (PubMed, Front Immunol)

We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.

2 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression

temozolomide • chlorpromazine

EAY131-S2: Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (clinicaltrials.gov)

P2, N=4, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027

2 days ago

Trial completion date

GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)

Mekinist (trametinib)

EAY131-S1: Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (clinicaltrials.gov)